ELEVANCE HEALTH, INC. (ELV) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.12%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.12% | Share-based compensation / revenue. Period ending 2026-06-30. $244.00M ÷ $201.11B × 100 ≈ 0.12% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 201.11B USD | |
| Stock-based compensation | 244.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 5.45B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $201.11B | $244.00M | $5.45B | (m) | (m) | 0.12% | (m) | (m) |
| 2026-03-31 | (m) | $200.41B | $250.00M | $6.12B | (m) | (m) | 0.12% | (m) | (m) |
| 2025-12-31 | (m) | $199.13B | $276.00M | $7.20B | (m) | (m) | 0.14% | (m) | (m) |
| 2025-09-30 | (m) | $194.82B | $217.00M | $7.56B | (m) | (m) | 0.11% | (m) | (m) |
| 2025-06-30 | (m) | $189.22B | $199.00M | $7.68B | (m) | (m) | 0.11% | (m) | (m) |
| 2025-03-31 | (m) | $183.32B | $210.00M | $8.02B | (m) | (m) | 0.11% | (m) | (m) |
| 2024-12-31 | (m) | $177.01B | $191.00M | $7.86B | (m) | (m) | 0.11% | (m) | (m) |
| 2024-09-30 | (m) | $174.22B | $292.00M | $8.47B | $1.10B | (m) | 0.17% | 7.67× | Reported |
| 2024-06-30 | (m) | $171.96B | $304.00M | $8.82B | $1.06B | (m) | 0.18% | 8.30× | Reported |
| 2024-03-31 | (m) | $171.75B | $290.00M | $8.68B | $1.04B | (m) | 0.17% | 8.32× | Reported |
| 2023-12-31 | (m) | $171.34B | $289.00M | $8.50B | $1.03B | (m) | 0.17% | 8.25× | Reported |
| 2023-09-30 | (m) | $168.62B | $290.00M | $8.47B | $1.00B | (m) | 0.17% | 8.47× | Reported |
| 2023-06-30 | (m) | $165.71B | $281.00M | $9.14B | $954.00M | (m) | 0.17% | 9.58× | Reported |
| 2023-03-31 | (m) | $160.67B | $275.00M | $8.86B | $901.00M | (m) | 0.17% | 9.83× | Reported |
| 2022-12-31 | (m) | $156.59B | $264.00M | $8.45B | $851.00M | (m) | 0.17% | 9.93× | Reported |
| 2022-09-30 | (m) | $153.25B | $250.00M | $8.27B | $822.00M | (m) | 0.16% | 10.06× | Reported |
| 2022-06-30 | (m) | $149.13B | $244.00M | $8.06B | $810.00M | (m) | 0.16% | 9.95× | Reported |
| 2022-03-31 | (m) | $144.35B | $241.00M | $7.78B | $807.00M | (m) | 0.17% | 9.63× | Reported |
| 2021-12-31 | (m) | $138.64B | $255.00M | $7.49B | $798.00M | (m) | 0.18% | 9.38× | Reported |
| 2021-09-30 | (m) | $133.88B | $265.00M | $6.91B | $789.00M | (m) | 0.20% | 8.75× | Reported |
| 2021-06-30 | (m) | $129.22B | $282.00M | $5.05B | $786.00M | (m) | 0.22% | 6.42× | Reported |
| 2021-03-31 | (m) | $124.63B | $280.00M | $6.33B | $782.00M | (m) | 0.22% | 8.09× | Reported |
| 2020-12-31 | (m) | $121.87B | $283.00M | $6.36B | $784.00M | (m) | 0.23% | 8.11× | Reported |
| 2020-09-30 | (m) | $117.45B | $282.00M | $6.85B | $783.00M | (m) | 0.24% | 8.75× | Reported |
| 2020-06-30 | (m) | $112.97B | $288.00M | $8.18B | $770.00M | (m) | 0.25% | 10.62× | Reported |
| 2020-03-31 | (m) | $109.17B | $291.00M | $6.25B | $753.00M | (m) | 0.27% | 8.30× | Reported |
| 2019-12-31 | (m) | $104.21B | $294.00M | $6.00B | $746.00M | (m) | 0.28% | 8.04× | Reported |
| 2019-09-30 | (m) | $100.18B | $317.00M | $5.65B | $745.00M | (m) | 0.32% | 7.59× | Reported |
| 2019-06-30 | (m) | $96.76B | $288.00M | $5.37B | $748.00M | (m) | 0.30% | 7.18× | Reported |
| 2019-03-31 | (m) | $94.23B | $254.00M | $5.50B | $756.00M | (m) | 0.27% | 7.27× | Reported |
| 2018-12-31 | (m) | $92.11B | $226.00M | $5.43B | $753.00M | (m) | 0.25% | 7.21× | Reported |
| 2018-09-30 | (m) | $91.41B | $173.60M | $5.06B | $728.00M | (m) | 0.19% | 6.95× | Reported |
| 2018-06-30 | (m) | $90.59B | $160.60M | $4.79B | $690.00M | (m) | 0.18% | 6.94× | Reported |
| 2018-03-31 | (m) | $90.05B | $169.10M | $4.46B | $688.20M | (m) | 0.19% | 6.48× | Reported |
| 2017-12-31 | (m) | $90.04B | $169.60M | $4.18B | $739.00M | (m) | 0.19% | 5.65× | Reported |
| 2017-09-30 | (m) | $89.07B | $171.00M | $4.45B | $752.70M | (m) | 0.19% | 5.91× | Reported |
| 2017-06-30 | (m) | $88.05B | $169.30M | $4.54B | $775.10M | (m) | 0.19% | 5.86× | Reported |
| 2017-03-31 | (m) | $87.10B | $169.70M | $4.82B | $770.90M | (m) | 0.19% | 6.25× | Reported |
| 2016-12-31 | (m) | $84.86B | $164.60M | $4.80B | $723.00M | (m) | 0.19% | 6.64× | Reported |
| 2016-09-30 | (m) | $83.34B | $161.50M | $4.59B | $725.40M | (m) | 0.19% | 6.33× | Reported |
| 2016-06-30 | (m) | $81.83B | $162.00M | $4.73B | $717.30M | (m) | 0.20% | 6.60× | Reported |
| 2016-03-31 | (m) | $80.39B | $158.70M | $4.74B | $685.70M | (m) | 0.20% | 6.92× | Reported |
| 2015-12-31 | (m) | $79.16B | $148.20M | $4.75B | $653.00M | (m) | 0.19% | 7.28× | Reported |
| 2015-09-30 | (m) | $77.95B | $154.20M | $5.20B | $626.90M | (m) | 0.20% | 8.29× | Reported |
| 2015-06-30 | (m) | $76.61B | $148.60M | $5.17B | $617.40M | (m) | 0.19% | 8.37× | Reported |
| 2015-03-31 | (m) | $75.07B | $157.20M | $4.88B | $608.90M | (m) | 0.21% | 8.01× | Reported |
| 2014-12-31 | (m) | $73.87B | $168.90M | $4.42B | $600.70M | (m) | 0.23% | 7.36× | Reported |
| 2014-09-30 | (m) | $72.79B | $168.00M | $3.95B | $592.90M | (m) | 0.23% | 6.67× | Reported |
| 2014-06-30 | (m) | $72.09B | $171.80M | $3.76B | $589.10M | (m) | 0.24% | 6.39× | Reported |
| 2014-03-31 | (m) | $71.31B | $163.30M | $3.76B | $595.40M | (m) | 0.23% | 6.32× | Reported |
| 2013-12-31 | (m) | $71.02B | $146.00M | $4.00B | $602.70M | (m) | 0.21% | 6.64× | Reported |
| 2013-09-30 | (m) | $68.99B | $126.50M | $4.04B | $608.40M | (m) | 0.18% | 6.64× | Reported |
| 2013-06-30 | (m) | $66.37B | (m) | $4.03B | $590.50M | (m) | (m) | 6.83× | Reported |
| 2013-03-31 | (m) | $63.98B | $135.50M | $3.79B | $556.20M | (m) | 0.21% | 6.82× | Reported |
| 2012-12-31 | (m) | $61.71B | $146.50M | $3.64B | $511.80M | (m) | 0.24% | 7.11× | Reported |
| 2012-09-30 | (m) | $61.49B | $160.40M | $3.72B | $472.90M | (m) | 0.26% | 7.87× | Reported |
| 2012-06-30 | (m) | $61.54B | $145.40M | $3.69B | $447.50M | (m) | 0.24% | 8.24× | Reported |
| 2012-03-31 | (m) | $61.23B | $144.70M | $3.64B | $433.50M | (m) | 0.24% | 8.41× | Reported |
| 2011-12-31 | (m) | $60.71B | $134.80M | $3.78B | $430.30M | (m) | 0.22% | 8.79× | Reported |
| 2011-09-30 | (m) | $60.12B | $137.50M | $3.96B | $430.70M | (m) | 0.23% | 9.20× | Reported |
| 2011-06-30 | (m) | $59.29B | $139.80M | $4.03B | $428.80M | (m) | 0.24% | 9.40× | Reported |
| 2011-03-31 | (m) | $58.62B | $144.50M | $4.14B | $425.40M | (m) | 0.25% | 9.73× | Reported |
| 2010-12-31 | (m) | $58.80B | $136.00M | $4.08B | $418.90M | (m) | 0.23% | 9.73× | Reported |
| 2010-09-30 | (m) | $63.20B | $134.50M | (m) | $409.60M | (m) | 0.21% | (m) | Reported |
| 2010-06-30 | (m) | $64.03B | $134.00M | (m) | $413.90M | (m) | 0.21% | (m) | Reported |
| 2010-03-31 | (m) | $64.98B | $142.90M | (m) | $430.70M | (m) | 0.22% | (m) | Reported |
| 2009-12-31 | (m) | $65.03B | $153.60M | (m) | $447.40M | (m) | 0.24% | (m) | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $61.25B | $156.00M | (m) | $469.80M | (m) | 0.25% | (m) | Reported |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $61.17B | $177.10M | (m) | $447.90M | (m) | 0.29% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cigna Group (CI) | United States | $70.160B | 10.44 |
| HUMANA INC (HUM) | United States | $45.651B | 18.44 |
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |